ADArif Nihat Demirci

Arif Nihat Demirci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arif Nihat Demirci has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Ramy Hanna

    Division of Nephrology, Department of Medicine, Hypertension and Kidney Transplantation, University of California, Irvine, Orange, USA

    2 shared publications
  • Caroline Gee

    Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplant, University of California, Irvine, USA

    1 shared publication
  • Dao Le

    Department of Medicine, University of California, Irvine, USA

    1 shared publication
  • Gayathri Dileep

    Division of Nephrology, Hypertension and Transplant Nephrology, University of California, Irvine, CA, USA

    1 shared publication
  • Jonathan Zuckerman

    David Geffen School of Medicine, Department of Pathology and Lab Medicine, University of California, Los Angeles, USA

    1 shared publication
  • Marrey Quizon

    Division of Nephrology, Hypertension and Transplant Nephrology, University of California, Irvine, CA, USA

    1 shared publication

Latest Publications

  • Open Access

    Immunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series

    by Ryan Fekrat, Arif Nihat Demirci, Caroline Gee, Sohrab Kharabaf, Mina Tadros, Matthew Nguyen, Dao Le, Omid Vadpey, Jonathan Zuckerman, Ramy Hanna

    Introduction: IgA nephropathy (IgAN) with concurrent thrombotic microangiopathy (TMA) is an unusual combination of pathological findings that is associated with severe hypertension, proteinuria, and lower estimated glomerular filtration rate (eGFR). This series presents 7 patients with kidney biopsies demonstrating IgAN and concomitant TMA and presents a link by way of complement disorder. Case presentation: Seven patients all presented as IgAN with associated TMA coinciding with hypertension, proteinuria, and low eGFR. Six patients showed tubular atrophy or interstitial fibrosis and 5 of those 6 showed >50% of renal cortex containing tubular atrophy or interstitial fibrosis. Variations of low serum C3, high serum C4, elevated IgA or IgM proteins, and elevated CH50 were found in 6 of the 7 patients. Conclusions: Chronic changes seen like interstitial fibrosis and tubular atrophy appear to show a subacute or chronic nature of IgAN with TMA. The low serum C3, high C4, elevated CH50, suggests complement activation in endothelial and mesangial from IgG-IgA complexes known to occur in IgAN. This phenotype of IgAN with TMA may represent a more unique IgAN phenotype with a more severe clinical course and be indicative of underlying complement dysregulation.

  • Open Access

    May-Hegglin anomaly associated nephropathy: Case series

    by Matthew D Nguyen, Gayathri Dileep, Marrey Quizon, Vu Nguyen, Arif Nihat Demirci, Ramy Hanna

    May-Hegglin anomaly (MHA) is a rare autosomal dominant disease associated with a mutation in the MYH-9 gene. It is characterized by macrothrombocytopenia and neutrophils with abnormal cytoplasmic inclusions. Clinical features of this disease include hearing loss, early cataracts, and renal failure. We present two interesting cases of renal injury attributed to MHA. The first is a 52-year-old Hispanic female with MHA-associated nephropathy and thrombocytopenia complicated by Stage 3 chronic kidney disease (CKD) and hypothyroidism. She was found to have a pathogenic MYH-9 heterozygous mutation with associated clinical characteristics. Due to her thrombocytopenia from MHA, patient is not a candidate for kidney biopsy. She has been treated with SGLT-2 inhibitors, Angiotensin Receptor Blockers (ARBs) for managing her Stage 3b CKD and Synthroid® for hypothyroidism. Despite these treatments, she continues to have low platelet counts, proteinuria, and progressive CKD. Our second case highlights a 39-year-old white female with MHA associated with focal segmental glomerulosclerosis diagnosed at the age of 15 on renal biopsy. She also has thrombocytopenia and mixed connective tissue disease with rheumatoid arthritis and systemic lupus erythematosus clinical characteristics. She is currently on a regimen of methotrexate, Xeljanz, and IVIG for her rheumatological diseases. Her kidney function has remained stable on Angiotensin Converting Enzyme Inhibitors (ACEi) with hydrochlorothiazide and as needed loop diuretics for edema. These cases illustrate the challenges of diagnosing and managing renal complications associated with MHA due to the MYH-9 gene mutation. Chronic thrombocytopenia in both patients restricts the use of invasive diagnostic procedures, such as biopsies, which are critical for confirming the relationship between nephropathy and MHA, and for guiding further treatment. As such, these cases stress the importance of genetic testing as a key tool in diagnosis and emphasize the difficulties in managing patients with suspected MHA-associated nephropathy and thrombocytopenia.